Résultats de la recherche - Heather Oakervee
- Résultat(s) 1 - 13 résultats de 13
-
1
Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up par Rakesh Popat, Heather Oakervee, Simon Hallam, Nicola Curry, Liz Odeh, Nicola Foot, Dixie‐Lee Esseltine, Mary Drake, Curly Morris, Jamie Cavenagh
Publié 2008Artigo -
2
-
3
PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma par Heather Oakervee, Rakesh Popat, Nicola Curry, Pat Smith, Curly Morris, Mary Drake, Samir Agrawal, Jim Stec, David P. Schenkein, Dixie‐Lee Esseltine, Jamie Cavenagh
Publié 2005Artigo -
4
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial par Rakesh Popat, Sarah Brown, Louise Flanagan, Andrew Hall, Walter M. Gregory, Bhuvan Kishore, Matthew Streetly, Heather Oakervee, Kwee Yong, Gordon Cook, Eric Low, Jamie Cavenagh
Publié 2016Artigo -
5
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma par Jamie Cavenagh, Heather Oakervee, P Baetiong-Caguioa, Faith E. Davies, Mecide Gharibo, Neil Rabin, Michael R. Kurman, Barbara Novak, Norihiko Shiraishi, Daisuke Nakashima, Shiro Akinaga, Kwee Yong
Publié 2017Artigo -
6
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction par David Taussig, Jacques Vargaftig, Farideh Miraki‐Moud, Emmanuel Griessinger, Kirsty Sharrock, Tina Luke, Debra M. Lillington, Heather Oakervee, Jamie Cavenagh, Samir Agrawal, Tim Lister, John G. Gribben, Dominique Bonnet
Publié 2010Artigo -
7
Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells par David Taussig, Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Daniel J. Pearce, Kirsty Allen, Christopher M. Ridler, Debra M. Lillington, Heather Oakervee, Jamie Cavenagh, Samir Agrawal, T. Andrew Lister, John G. Gribben, Dominique Bonnet
Publié 2008Artigo -
8
Differential and tumor-specific expression of CD160 in B-cell malignancies par Timothy Farren, Jérôme Giustiniani, Fengting Liu, Dimitris A. Tsitsikas, Marion G. Macey, James D. Cavenagh, Heather Oakervee, David Taussig, Adrian C. Newland, Maria Calaminici, Armand Bensussan, Michael Jenner, John G. Gribben, Samir Agrawal
Publié 2011Artigo -
9
Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation par Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Katharine Hodby, Emmanuel Griessinger, Guglielmo Rosignoli, Debra M. Lillington, Li Jia, Jeff Davies, Jamie Cavenagh, Matthew L. Smith, Heather Oakervee, Samir Agrawal, John G. Gribben, Dominique Bonnet, David Taussig
Publié 2013Artigo -
10
Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients par James Aries, Jeffrey K. Davies, Rebecca L. Auer, Simon Hallam, Silvia Montoto, Matthew D. Smith, Belen Sevillano, Vanessa Foggo, Bela Wrench, Krzysztof Zegocki, Samir Agrawal, Rifca Le Dieu, Edward Truelove, Thomas Erblich, Shamzah Araf, Jessica Okosun, Heather Oakervee, Jamie Cavenagh, John G. Gribben, John C. Riches
Publié 2020Carta -
11
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma par Ivan Špıčka, Enrique M. Ocio, Heather Oakervee, Richard Greil, Raymond H. Banh, Shang‐Yi Huang, James M. D’Rozario, Meletios Α. Dimopoulos, Sara Martínez, Sonia Extremera, Carmen Kahatt, Vicente Alfaro, Angelo Michele Carella, Nathalie Meuleman, Roman Hájek, Argiris Symeonidis, Chang‐Ki Min, Paul Cannell, Heinz Ludwig, Pieter Sonneveld, María‐Victoria Mateos
Publié 2019Artigo -
12
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma par Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Philippe Moreau, María‐Victoria Mateos, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesús F. San Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C. Anderson, Paul G. Richardson
Publié 2015Artigo -
13
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study par Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesús F. San Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Morio Matsumoto, Ka Lung Wu, Kenneth C. Anderson, Ying‐Ming Jou, Alex Ganetsky, Anil Singhal, Paul G. Richardson
Publié 2020Artigo
Outils de recherche:
Sujets similaires
Medicine
Internal medicine
Multiple myeloma
Bortezomib
Dexamethasone
Biology
Oncology
Cancer research
Chemotherapy
Immunology
Leukemia
Adverse effect
CD34
CD38
Cell biology
Gastroenterology
Haematopoiesis
Lenalidomide
Myeloid leukemia
Stem cell
Antibody
Astrobiology
Cancer
Clinical endpoint
Confidence interval
Doxorubicin
Hazard ratio
Intensive care medicine
Myeloid
Nausea